We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

55 hedge funds and large institutions have $200M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

30% more capital invested

Capital invested by funds: $154M → $200M (+$46.7M)

0% more funds holding

Funds holding: 55 → 55 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
55
Holders Change
–
Holders Change %
0%
% of All Funds
1.59%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
25
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCI
Columbus Circle Investors
+$11.8M
2
CCM
Cupps Capital Management
Illinois
+$4.34M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$4.3M
4
Bank of America
Bank of America
North Carolina
+$2.99M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$3.39M
2
TG
TCW Group
California
-$1.76M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.67M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$600K
5
EMG
Ellington Management Group
Connecticut
-$440K
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
26
ProShare Advisors
Maryland
$917K +$495K +14,684 +117%
TAM
27
Tocqueville Asset Management
New York
$872K +$556K +16,500 +176%
Federated Hermes
28
Federated Hermes
Pennsylvania
$837K +$738K +21,909 +736%
RFC
29
Russell Frank Company
Washington
$695K +$252K +7,465 +39%
CAM
30
ClariVest Asset Management
California
$647K +$648K +19,241 New
HCM
31
Hodges Capital Management
Texas
$505K – – –
Goldman Sachs
32
Goldman Sachs
New York
$474K -$437K -12,978 -48%
BIM
33
BlackRock Investment Management
Delaware
$455K +$23.5K +696 +5%
TG
34
TCW Group
California
$439K -$1.76M -52,328 -80%
TCIM
35
TIAA CREF Investment Management
New York
$427K – – –
Charles Schwab
36
Charles Schwab
California
$423K +$10.1K +300 +2%
CS
37
Credit Suisse
Switzerland
$422K +$422K +12,529 New
FMT
38
First Mercantile Trust
Tennessee
$375K +$375K +11,120 New
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$370K +$135K +4,000 +57%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$291K +$209K +6,195 +124%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$286K – – –
AIG
42
American International Group
New York
$220K +$52.5K +1,559 +31%
TA
43
Teachers Advisors
New York
$216K – – –
HLA
44
Hamilton Lane Advisors
Pennsylvania
$204K +$205K +6,073 New
Barclays
45
Barclays
United Kingdom
$169K +$168K +4,996 +3,446%
U
46
UBS
Switzerland
$128K +$69.4K +2,059 +118%
NFA
47
Nationwide Fund Advisors
Ohio
$122K – – –
BA
48
BlackRock Advisors
Delaware
$117K -$218K -6,462 -65%
Citigroup
49
Citigroup
New York
$100K -$42.9K -1,273 -30%
MCM
50
Mazama Capital Management
Oregon
$51K -$78.9K -2,342 -61%
1
2
3

OMED Hedge Fund Activity: Q1 2014 in Review

55 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2014, worth a combined $200M — up 30% from $154M a quarter earlier.

Fund positioning in OMED was balanced in Q1 2014: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 12 trimmed.

The largest buyer was Columbus Circle Investors, adding an estimated $11.8M. The largest seller was BVF Inc, cutting an estimated $3.39M.

  • 55 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2014, unchanged from Q4 2013.
  • Funds reported $200M of OncoMed Pharmaceuticals, Inc. stock for Q1 2014, up 30% quarter-over-quarter.
  • 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2014 and 8 closed out, a net change of 0 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2014 was Columbus Circle Investors, an estimated $11.8M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2014 was BVF Inc, an estimated $3.39M sold.

Based on aggregated 13F filings for Q1 2014.